Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities

ChemMedChem

Volumn 9, Issue 3, 2014, Pages 638-648

  Zhang, Lei ^a   Zhang, Yingjie ^b   Chou, C James ^c   Inks, Elizabeth S ^c   Wang, Xuejian ^d   Li, Xiaoguang ^b   Hou, Jinning ^b   Xu, Wenfang ^b  

^a QINGDAO UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

antitumor agents; cancer; epigenetics; histone deacetylases; inhibitors; structural optimization

Indexed keywords

2 CHLORO N [2 [(4 (HYDROXYCARBAMOYL)PHENYL]AMINO] 2 OXO 1 PHENYLETHYL)BENZAMIDE; 3 BROMO N [2 [(4 (HYDROXYCARBAMOYL)PHENYL]AMINO] 2 OXO 1 PHENYLETHYL)BENZAMIDE; 4 (2 BENZAMIDO 2 PHENYLACETAMIDO) N HYDROXYBENZAMIDE; 4 [2 (2,6 DIFLUOROPHENYLSULFONAMIDO) 2 PHENYLACETAMIDO] N HYDROXYBENZAMIDE; 4 [2 (4 CHLOROPHENYLSULFONAMIDO) 2 PHENYLACETAMIDO] N HYDROXYBENZAMIDE; 4 [2 [3 (2,6 DIISOPROPYLPHENYL)UREIDO] 2 PHENYLACETAMIDO] N HYDROXYBENZAMIDE; 4 [2 [4 (TERT BUTYL)PHENYLSULFONAMIDO] 2 PHENYLACETAMIDO] N HYDROXYBENZAMIDE; 4 [2 [5 (DIMETHYLAMINO)NAPHTHALENE 1 SULFONAMIDO] 2 PHENYLACETAMIDO] N HYDROXYBENZAMIDE; 4 CHLORO N [2 [(4 (HYDROXYCARBAMOYL)PHENYL]AMINO] 2 OXO 1 PHENYLETHYL]BENZAMIDE; 4 FLUORO N [2 [(4 (HYDROXYCARBAMOYL)PHENYL]AMINO] 2 OXO 1 PHENYLETHYL]BENZAMIDE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; N [2 [[4 (HYDROXYCARBAMOYL)PHENYL]AMINO] 2 OXO 1 PHENYL ETHYL] 2 NAPHTHAMIDE; N [2 [[4 (HYDROXYCARBAMOYL)PHENYL]AMINO] 2 OXO 1 PHENYLETHYL] 2 METHOXYBENZAMIDE; N HYDROXY 4 [2 (4 METHOXYBENZAMIDO) 2 PHENYLACETAMIDO]BENZAMIDE; N HYDROXY 4 [2 (NAPHTHALENE 1 SULFONAMIDO) 2 PHENYLACETAMIDO]BENZAMIDE; N HYDROXY 4 [2 (NAPHTHALENE 2 SULFONAMIDO) 2 PHENYLACETAMIDO]BENZAMIDE; N HYDROXY 4 [2 [3 (2 METHOXYPHENYL)UREIDO] 2 PHENYLACETAMIDO]BENZAMIDE; N HYDROXY 4 [2 PHENYL 2 (2 PHENYLACETAMIDO)ACETAMIDO]BENZAMIDE; N HYDROXY 4 [2 PHENYL 2 (2 PROPYLPENTANAMIDO)ACETAMIDO]BENZAMIDE; N HYDROXY 4 [2 PHENYL 2 [4 (TRIFLUOROMETHYL)PHENYLSULFONAMIDO]ACETAMIDO]BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN HL 60; CELL STRAIN K 562; CELL STRAIN U937; CONTROLLED STUDY; DOWN REGULATION; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIC MONOCYTE LYMPHOMA; LYMPHOMA; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTITUMOR AGENTS; CANCER; EPIGENETICS; HISTONE DEACETYLASES; INHIBITORS; STRUCTURAL OPTIMIZATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HL-60 CELLS; HUMANS; MCF-7 CELLS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; U937 CELLS;

EID: 84896700010     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201300297     Document Type: Article

References (30)

1. B. E. Bernstein, J. K. Tong, S. L. Schreiber, Proc. Natl. Acad. Sci. USA 2000, 97, 13708-13713
2. A. J. M. Dea Ruijter, A. H. Vana Gennip, H. N. Caron, S. Kemp, A. B. P. Vana Kuilenburg, Biochem. J. 2003, 370, 737-749
3. C. Foglietti, G. Filocamo, E. Cundari, E. Dea Rinaldis, A. Lahm, R. Cortese, C. Steinkuhler, J. Biol. Chem. 2006, 281, 17968-17976.
4. E. Grönroos, U. Hellman, C. H. Heldin, J. Ericsson, Mol. Cell 2002, 10, 483-493
5. V. Giandomenico, M. Simonsson, E. Grönroos, J. Ericsson, Mol. Cell. Biol. 2003, 23, 2587-2599
6. Y. H. Jin, E. J. Jeon, Q. L. Li, Y. H. Lee, J. K. Choi, W. J. Kim, K. Y. Lee, S. C. Bae, J. Biol. Chem. 2004, 279, 29409-29417.
7. A. M. Bode, Z. G. Dong, Nat. Rev. Cancer 2004, 4, 793-805
8. L. F. Chen, W. C. Greene, Nat. Rev. Mol. Cell Biol. 2004, 5, 392-401
9. J. J. Kovacs, P. J. M. Murphy, S. Gaillard, X. A. Zhao, J. T. Wu, C. V. Nicchitta, M. Yoshida, D. O. Toft, W. B. Pratt, T. P. Yao, Mol. Cell 2005, 18, 601-607.
10. P. A. Marks, R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, W. K. Kelly, Nat. Rev. Cancer 2001, 1, 194-202.
11. S. A. M. Thiagalingam, K.-H. Cheng, H. J. Lee, N. Mineva, A. Thiagalingam, J. F. Ponte, Ann. N. Y. Acad. Sci. 2003, 983, 84-100
12. P. A. Marks, V. M. Richon, R. A. Rifkind, J. Natl. Cancer Inst. 2000, 92, 1210-1216.
13. V. M. Richon, S. Emiliani, E. Verdin, Y. Webb, R. Breslow, R. A. Rifkind, P. A. Marks, Proc. Natl. Acad. Sci. USA 1998, 95, 3003-3007.
14. H. Ueda, H. Nakajima, Y. Hori, T. Fujita, M. Nishimura, T. Goto, M. Okuhara, J. Antibiot. 1994, 47, 301-310.
15. L. Zhang, M. Y. Li, J. H. Feng, H. Fang, W. F. Xu, Med. Chem. Res. 2012, 21, 152-156
16. L. Zhang, X. Wang, X. Li, W. Xu, J. Enzyme Inhib. Med. Chem. 2013, DOI:.
17. I. Verbrugge, R. W. Johnstone, M. Bots, Epigenomics 2011, 3, 547-565
18. B. E. Gryder, Q. H. Sodji, A. K. Oyelere, Future Med. Chem. 2012, 4, 505-524.
19. G. Garcia-Manero, H. Yang, C. Bueso-Ramos, A. Ferrajoli, J. Cortes, W. G. Wierda, S. Faderl, C. Koller, G. Morris, G. Rosner, A. Loboda, V. R. Fantin, S. S. Randolph, J. S. Hardwick, J. F. Reilly, C. Chen, J. L. Ricker, J. P. Secrist, V. M. Richon, S. R. Frankel, H. M. Kantarjian, Blood 2008, 111, 1060-1066
20. J. Vansteenkiste, E. Vana Cutsem, H. Dumez, C. Chen, J. L. Ricker, S. S. Randolph, P. Schoffski, Invest. New Drugs 2008, 26, 483-488
21. P.a N. Munster, M. Lacevic, M. Schmitt, E. Bicaku, D. Marchion, A. Stephens, L. Sullivan, S. Minton, J. Clin. Oncol. 2008, 26, 3501 (meeting abstract)
22. E. Galanis, K. A. Jaeckle, M. J. Maurer, J. M. Reid, M. M. Ames, J. S. Hardwick, J. F. Reilly, A. Loboda, M. Nebozhyn, V. R. Fantin, V. M. Richon, B. Scheithauer, C. Giannini, P. J. Flynn, D. F. Moore,a Jr., J. Zwiebel, J. C. Buckner, J. Clin. Oncol. 2009, 27, 2052-2058
23. K. Hymes, R. Dummer, W. Sterry, M. Steinhoff, C. Assaf, H. Kerl, J. Ahern, S. Rizvi, J.a L. Ricker, S. Whittaker, J. Clin. Oncol. 2008, 26, 8613 (meeting abstract)
24. M. Duvic, E. A. Olsen, D. Breneman, T. R. Pacheco, S. Parker, E. C. Vonderheid, R. Abuav, J. L. Ricker, S. Rizvi, C. Chen, K. Boileau, A. Gunchenko, C. Sanz-Rodriguez, L. J. Geskin, Clin. Lymphoma Myeloma 2009, 9, 412-416
25. R. L. Piekarz, R. Robey, V. Sandor, S. Bakke, W. H. Wilson, L. Dahmoush, D. M. Kingma, M. L. Turner, R. Altemus, S. E. Bates, Blood 2001, 98, 2865-2868
26. W. M. Stadler, K. Margolin, S. Ferber, W. McCulloch, J. A. Thompson, Clinical Genitourin. Cancer 2006, 5, 57-60
27. D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, E. Kruchin, J. J. Wright, D. R. Rosing, A. Sparreboom, W. D. Figg, S. M. Steinberg, Clin. Cancer Res. 2008, 14, 188-198
28. R. P. Whitehead, C. Rankin, P. M. G. Hoff, P. J. Gold, K. G. Billingsley, R. A. Chapman, L. Wong, J. H. Ward, J. L. Abbruzzese, C. D. Blanke, Invest. New Drugs 2009, 27, 469-475.
29. Y. J. Zhang, J. H. Feng, C. X. Liu, L. Zhang, J. Jiao, H. Fang, L. Su, X. P. Zhang, J. Zhang, M. Y. Li, B. H. Wang, W. F. Xu, Bioorg. Med. Chem. 2010, 18, 1761-1772.
30. J. Feng, H. Fang, X. Wang, Y. Jia, L. Zhang, J. Jiao, J. Zhang, L. Gu, W. Xu, Cancer Biol. Ther. 2011, 11, 477-489.